A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to measure how much of the study drug called baricitinib
gets into the blood stream and how long it takes the body to get rid of it. Healthy
participants and those with liver disease may enroll. The study will last about 7 days for
each participant, not including screening.